In this study, 73 matched neoplastic tissue and plasma DNA samples and 54 plasma DNA samples from healthy individuals were examined for the diagnostic utility of ctDNA in thyroid cancers focusing on BRAF, KRAS, NRAS, and TERT promoter mutations. The gene discussed is KRAS; the disease is thyroid gland carcinoma.